The in vitro activity of LY163892, a synthetic oral cephalosporin, was compared with those of cefaclor and cefuroxime against 1,193 clinical isolates. MIC ranges and MICs for 50 and 90% of isolates of the three cephalosporins were comparable. The activities of LY163892 and cefaclor were, however, highly inoculum dependent against P-lactamase-positive Haemophilus influenzae and Staphylococcus aureus; that of cefuroxime was not. LY163892 and cefuroxime appeared stable in microdilution trays stored at 5 and -20°C for 5 weeks, in contrast to cefaclor which remained stable for more than a week only at -5°C.
phenylacetyl)amino]-3-chloro-8-oxo-1-azabicyclo[4.2.O]oct-
2-ene-2-carboxylic acid} that is similar in structure and activity to cefaclor but that appears to have greater stability in vitro than cefaclor.
The purposes of this study were (i) to compare the antibacterial activities of LY163892, cefaclor, and cefuroxime, which has increased stability to plasmid-mediated ,Blactamases (8, 9) and from which has been developed an orally administered ester, cefuroxime axetil (4); (ii) to determine inoculum effects of 3-lactamase-producing H. influenzae and Staphylococcus aureus on LY163892, cefaclor, and cefuroxime; and (iii) to assess the stabilities of LY 163892, cefaclor, and cefuroxime under refrigerated and frozen storage conditions.
A total of 1,193 clinical isolates were tested by a broth microdilution method, as recommended by the National Committee for Clinical Laboratory Standards (6 For stability studies, 20 microdilution trays containing LY163892, cefaclor, and cefuroxime in serial log2 dilutions were prepared, and 10 trays each were stored at 5 and -20°C. Two trays from each storage condition were removed each week, allowed to adjust to room temperature, and inoculated with S. aureus ATCC 29213 and E. coli ATCC 25922.
MICs for groups, genera, or species represented by nine or more strains each are listed in Table 1 , and MICs for groups, genera, or species represented by five or fewer strains each are listed separately in Table 2 . LY163892, cefaclor, and cefuroxime MIC ranges and MICs for 50 and 90% of isolates were the same for ,-lactamase-positive and 3-lactamase-negative strains of H. influenzae and are, therefore, not listed separately in Table 1 . MICs of LY163892, cefaclor, and cefuroxime against a 3-lactamase-negative, ampicillin-resistant strain of H. influenzae were 64, >64, and 16 ,ug/ml, respectively. Of a total of 23 methicillin-resistant staphylococci tested, 4 were inhibited by 16 jig and 1 was inhibited by 32 jLg of LY163892 per ml, while the remainder were resistant to 64 ,ug of LY163892 per ml. MICs of cefaclor and cefuroxime were within control limits for S. aureus ATCC 29213, E. coli ATCC 25922, and E. faecalis ATCC 29212; the corresponding MICs of LY163892 were, respectively, 1 to 2, 0.5 to 1, and 64 ,ug/ml. LY163892 and cefaclor had inoculum-dependent activity against ,-lactamase-positive H. influenzae and S. aureus (Table 3) . No inoculum effect was seen with cefuroxime when it was tested against these same strains. These observations may reflect the greater stability of cefuroxime relative to those of cefaclor and, presumably, LY163892 to staphylococcal and H. influenzae ,-lactamases (2, 5, 8, 9 In conclusion, the spectrum of activity of LY163892 is comparable to those of cefaclor and, in many respects, cefuroxime. In contrast to that of cefuroxime, the activities of both LY163892 and cefaclor were adversely affected by increased inocula of ,3-lactamase-positive H. influenzae and S. aureus. The stability of LY163892 was considerably greater than that of cefaclor under 5°C storage conditions.
